Mepolizumab for eosinophilic chronic obstructive pulmonary disease

Mepolizumab for eosinophilic chronic obstructive pulmonary disease

Patients with chronic obstructive pulmonary disease (COPD) with an eosinophilic phenotype may benefit from treatment with mepolizumab, a monoclonal antibody directed against interleukin-5.We performed two phase 3, randomized, placebo-controlled, double-blind, parallel-group trials comparing mepolizu...

Πλήρης περιγραφή

Λεπτομέρειες βιβλιογραφικής εγγραφής
Κύριοι συγγραφείς:	Pavord, I, Chanez, P, Criner, G, Kerstjens, H, Korn, S, Lugogo, N, Martinot, J, Sagara, H, Albers, F, Bradford, E, Harris, S, Mayer, B, Rubin, D, Yancey, S, Sciurba, F
Μορφή:	Journal article
Γλώσσα:	English
Έκδοση:	Massachusetts Medical Society 2017

Παρόμοια τεκμήρια

Late breaking abstract - Dose-ranging study of mepolizumab in eosinophilic COPD
ανά: Pavord, I, κ.ά.
Έκδοση: (2017)

Mepolizumab for Eosinophilic Chronic Obstructive Pulmonary Disease (COPD): A Meta-Analysis of METREX and METREO Exacerbation Endpoints
ανά: Bafadhel, M, κ.ά.
Έκδοση: (2018)

Mepolizumab for eosinophilic COPD
ανά: Sciurba, F, κ.ά.
Έκδοση: (2018)

Mepolizumab for Eosinophilic Chronic Obstructive Pulmonary Disease (COPD): A Meta-Analysis of METREX and METREO Patient-Reported Outcomes, Response to Therapy and Lung Function
ανά: Chapman, K, κ.ά.
Έκδοση: (2018)

Evaluation of potential continuation rules for mepolizumab treatment of severe eosinophilic asthma.
ανά: Gunsoy, N, κ.ά.
Έκδοση: (2017)

Mepolizumab treatment in patients with severe eosinophilic asthma.
ανά: Ortega, H, κ.ά.
Έκδοση: (2014)

Glucocorticoids and mepolizumab in eosinophilic asthma.
ανά: Bel, E, κ.ά.
Έκδοση: (2014)

Fractional exhaled nitric oxide and the peripheral blood eosinophil count as biomarkers of the response to mepolizumab in patients with severe eosinophilic asthma
ανά: Shrimanker, R, κ.ά.
Έκδοση: (2018)

Mepolizumab in the treatment of eosinophilic chronic obstructive pulmonary disease
ανά: Mkorombindo T, κ.ά.
Έκδοση: (2019-08-01)

Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial.
ανά: Pavord, I, κ.ά.
Έκδοση: (2012)

Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma.
ανά: Bel, E, κ.ά.
Έκδοση: (2014)

Efficacy of add-on mepolizumab in adolescents with severe eosinophilic asthma
ανά: Steven W. Yancey, κ.ά.
Έκδοση: (2019-09-01)

Severe eosinophilic asthma treated with mepolizumab stratified by baseline eosinophil thresholds: a secondary analysis of the DREAM and MENSA studies.
ανά: Ortega, H, κ.ά.
Έκδοση: (2016)

Meta-analysis of asthma-related hospitalization in mepolizumab studies of severe eosinophilic asthma
ανά: Yancey, S, κ.ά.
Έκδοση: (2016)

Mepolizumab in refractory eosinophilic asthma.
ανά: Pavord, I, κ.ά.
Έκδοση: (2010)

Mepolizumab, quality of life, and severe eosinophilic asthma.
ανά: Pavord, I
Έκδοση: (2017)

Clinical characterisation of exacerbations of severe eosinophilic asthma occurring on mepolizumab and placebo
ανά: Howell, I, κ.ά.
Έκδοση: (2024)

Response to Mepolizumab Treatment in Patients with Severe Eosinophilic Asthma and Atopic Phenotypes
ανά: Prazma CM, κ.ά.
Έκδοση: (2021-06-01)

Evaluation of sputum eosinophil count as a predictor of treatment response to mepolizumab
ανά: Ian D. Pavord, κ.ά.
Έκδοση: (2022-05-01)

Clinical characterisation of exacerbations of severe eosinophilic asthma occurring on mepolizumab and placebo
ανά: Imran Howell, κ.ά.
Έκδοση: (2024-07-01)

Efficacy and safety of mepolizumab in Japanese patients with severe eosinophilic asthma
ανά: Terufumi Shimoda, κ.ά.
Έκδοση: (2017-07-01)

Mepolizumab or placebo for eosinophilic granulomatosis with polyangiitis
ανά: Wechsler, M, κ.ά.
Έκδοση: (2017)

Blood eosinophil depletion with mepolizumab, benralizumab and prednisolone in eosinophilic asthma
ανά: Moran, AM, κ.ά.
Έκδοση: (2020)

Mepolizumab and exacerbations of refractory eosinophilic asthma.
ανά: Haldar, P, κ.ά.
Έκδοση: (2009)

Response to mepolizumab treatment is sustained across 4-weekly dosing periods
ανά: Ian D. Pavord, κ.ά.
Έκδοση: (2020-09-01)

Efficacy and safety of mepolizumab in Korean patients with severe eosinophilic asthma from the DREAM and MENSA studies
ανά: Mi-Kyeong Kim, κ.ά.
Έκδοση: (2021-03-01)

Mepolizumab reduces exacerbations in patients with severe eosinophilic asthma, irrespective of body weight/body mass index: meta-analysis of MENSA and MUSCA
ανά: Frank C. Albers, κ.ά.
Έκδοση: (2019-07-01)

Treatment of eosinophilic myositis with mepolizumab
ανά: Saadia Waheed, κ.ά.
Έκδοση: (2018-01-01)

GLUCOLD, eosinophils and chronic obstructive pulmonary disease
ανά: Pavord, I
Έκδοση: (2018)

Mepolizumab and the response to oral prednisolone in patients with severe eosinophilic asthma
ανά: Shrimanker, R, κ.ά.
Έκδοση: (2017)

Biomarkers for severe eosinophilic asthma.
ανά: Yancey, S, κ.ά.
Έκδοση: (2017)

Clinical usefulness of mepolizumab in severe eosinophilic asthma
ανά: Menzella F, κ.ά.
Έκδοση: (2016-06-01)

Characterisation of exacerbations of severe eosinophilic asthma (SEA) on mepolizumab compared to placebo
ανά: Shrimanker, R, κ.ά.
Έκδοση: (2017)

Depletion rate of blood eosinophils with mepolizumab, benralizumab and oral prednisolone in patients with severe asthma
ανά: Moran, A, κ.ά.
Έκδοση: (2020)

Clinical Benefit of Mepolizumab in Eosinophilic Granulomatosis With Polyangiitis for Patients With and Without a Vasculitic Phenotype
ανά: Benjamin Terrier, κ.ά.
Έκδοση: (2023-07-01)

Blood eosinophil phenotype during treatment with mepolizumab in patients with severe eosinophilic asthma
ανά: Chio Sakai, κ.ά.
Έκδοση: (2024-07-01)

Mepolizumab-responsive recurrent eosinophilic eruption without peripheral eosinophilia
ανά: Nina B. Curkovic, MD, κ.ά.
Έκδοση: (2024-11-01)

Safety and Efficacy of Mepolizumab in Patients with Eosinophilic Granulomatosis with Polyangiitis
ανά: Ravi Ranjan Pradhan, κ.ά.
Έκδοση: (2019-01-01)

Effectiveness of mepolizumab for eosinophilic pneumonia following bronchial thermoplasty
ανά: Ryota Otoshi, κ.ά.
Έκδοση: (2020-03-01)

Remission outcomes in severe eosinophilic asthma with mepolizumab therapy: Analysis of the REDES study
ανά: Ian Pavord, κ.ά.
Έκδοση: (2023-04-01)